Risk factor
Negligible price volatility
Profitability factor
Somewhat favourable analyst view
About
Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. The company operates through Medical Services; Education; and Trading, Retail & Others segments. It provides various services, such as assisted reproductive therapy, audiology, bariatric surgery, pediatric, breast feeding, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial, dermatology, otorhinolaryngology, endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen service, infectious diseases, internal medicine, interventional radiology, psychiatry, lasik surgery, nephrology, neuro surgery, neurology, nutrition, obstetrics and gynecology, oncology, orthopedics, pediatric orthopedic surgery, pediatric surgery, physical medicine and rehabilitation, plastic surgery, rheumatology, sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery, as well as pain treatment and palliative care services. The company also operates AIRS, anesthesia, burn, diagnostics service, emergency medicine, endoscopy, intensive care, NICU, renal dialysis, rhinoplasty, and institute of robotic surgery facilities; establishes and manages pharmacies; and provides analysis and radiology laboratory, healthcare, medical education, and home health care services. In addition, it engages in the trading of pharmaceutical products, spectacles, and cosmetics; construction and contracting; wholesale and retail of medical equipment; and maintenance of IT equipment and software related services. The company was incorporated in 1978 and is based in Jeddah, the Kingdom of Saudi Arabia.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value
Target Price
The average target price of 4017.SR is 38.7 and suggests 26.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i